Matthew M. Cornelison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Matthew M. Cornelison has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Darien L. Stratton
Division of Medical Toxicology, Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
1 shared publication - Geoffrey Smelski
College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
1 shared publication - Hannah L. Nakamura
University of Arizona, Arizona Poison and Drug Information Center, Tucson, AZ, USA
1 shared publication - Tyler M. Hoelscher
Poison Control Center, The University of Arizona College of Pharmacy, Tucson, AZ 85724, USA
1 shared publication - Vance Girard Nielsen
Department of Anesthesiology, College of Medicine, University of Arizona, Tucson, AZ 85750, USA
1 shared publication - William Rushton
Department of Emergency Medicine, University of Alabama at Birmingham
1 shared publication
Latest Publications
- Open Access
Antivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain
The onset, progression, and severity of pain following rattlesnake envenomation are highly variable between patients. Pain can be severe and persistent, seemingly refractory to opioid analgesics. The ability of antivenom to directly relieve pain has not been well studied. We reviewed poison center charts of rattlesnake envenomations between 1 January 2018, and 31 December 2022. Demographic data as well as details of antivenom usage and pain severity were collected. Patients were coded in one of three categories: without pain (Pain 0), well controlled pain (Pain 1), and opioid refractory pain (Pain 2). A total of 289 patients met the inclusion criteria, with 140 receiving Anavip antivenom and 149 receiving Crofab. Patient characteristics were different between both cohorts. There were no significant differences in the number of Anavip vials used between the Pain 1 and Pain 2 groups. However, patients in the Crofab Pain 2 group received more antivenom compared to Pain 1. Importantly, Pain 3 patients were treated with the highest amount of antivenom in both the Crofab and Anavip cohorts. Despite the higher doses of antivenom used, these patients also experienced the greatest pain. These data suggest that antivenom alone may have minimal analgesic benefits.
Open AccessAntivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain
The onset, progression, and severity of pain following rattlesnake envenomation are highly variable between patients. Pain can be severe and persistent, seemingly refractory to opioid analgesics. The ability of antivenom to directly relieve pain has not been well studied. We reviewed poison center charts of rattlesnake envenomations between 1 January 2018, and 31 December 2022. Demographic data as well as details of antivenom usage and pain severity were collected. Patients were coded in one of three categories: without pain (Pain 0), well controlled pain (Pain 1), and opioid refractory pain (Pain 2). A total of 289 patients met the inclusion criteria, with 140 receiving Anavip antivenom and 149 receiving Crofab. Patient characteristics were different between both cohorts. There were no significant differences in the number of Anavip vials used between the Pain 1 and Pain 2 groups. However, patients in the Crofab Pain 2 group received more antivenom compared to Pain 1. Importantly, Pain 3 patients were treated with the highest amount of antivenom in both the Crofab and Anavip cohorts. Despite the higher doses of antivenom used, these patients also experienced the greatest pain. These data suggest that antivenom alone may have minimal analgesic benefits.